Related Experiment Videos
[Transcutaneous radiotherapy after thyroidectomy for differentiated thyroid carcinoma]
L Busutti1, A B Blotta, G Calò-Gabrieli
1Radioterapia Azienda Ospedaliera Sant' Orsola-Malpighi, Bologna, Italia.
La Clinica Terapeutica
|July 9, 1999
Summary
External beam radiotherapy (RT) combined with I-131 therapy significantly improves 10-year survival for differentiated thyroid cancer patients with advanced disease. This combination therapy is particularly beneficial for those with extracapsular tumor extension or tracheal involvement.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiotherapy
Background:
- Differentiated thyroid carcinoma (DTC) management often involves surgery followed by radioactive iodine (I-131) therapy.
- The role of adjuvant external beam radiotherapy (RT) in improving outcomes for DTC patients remains an area of investigation, particularly for those with advanced disease.
- Assessing long-term survival benefits and toxicity profiles is crucial for optimizing treatment strategies.
Purpose of the Study:
- To compare the 10-year actuarial survival rates between I-131 therapy alone and I-131 therapy combined with external beam radiotherapy (RT) in surgically treated differentiated thyroid carcinoma patients.
- To evaluate the impact of adjuvant RT on survival outcomes in specific subgroups of DTC patients, including those with advanced tumor stages and nodal involvement.
Main Methods:
- A retrospective analysis of 408 patients who underwent thyroidectomy for differentiated thyroid carcinoma between 1982 and 1995.
- Patients were divided into two comparable groups: Group A (165 patients) received surgery + I-131 therapy, and Group B (243 patients) received surgery + I-131 therapy + RT.
- Survival was assessed over a 10-year period, with statistical analysis to determine significant differences between treatment groups.
Main Results:
- The overall mortality rate related to recurrent or metastatic thyroid carcinoma was 6.25%.
- Adjuvant RT was associated with a statistically significant improvement in 10-year survival (p < 0.01), especially in patients with extracapsular tumor diffusion.
- Acute side effects (tracheal/esophageal) occurred in 14.8% of patients receiving adjuvant RT, while late toxicities (mouth dryness, fibrosis) were observed in 2.4%.
Conclusions:
- Adjuvant external beam radiotherapy (RT) significantly enhances the 10-year survival of differentiated thyroid carcinoma patients, particularly those with extracapsular tumor spread.
- The benefit of adjuvant RT is especially pronounced in patients with pT4 N1b tumors or those with tumors invading the trachea.
- While adjuvant RT increases the risk of acute side effects, the survival benefit in high-risk patients justifies its consideration in treatment planning.